GSE200530
Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2
Gene-based therapeutic strategies to lower ataxin-2 levels are emerging for neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). To identify additional ways of reducing ataxin-2 levels, we performed a genome-wide screen in human cells for regulators of ataxin-2 and identified RTN4R, the gene encoding the RTN4/NoGo-Receptor, as a top hit. This dataset contains the RNA-sequencing data used to support the conclusions from this study. Overall design: Transcriptional changes in RTN4R shRNA knockdown compared to non-targeting shRNA condition in iPSC-derived neurons (iNs). Differential gene expressoin derived from RNA-sequencing data, analyzed using DESeq2.